Telmisartan Plus Propranolol Improves Liver Fibrosis and Bile Duct Proliferation in the PSC-Like Abcb4−/− Mouse Model
Authors:
- Susanne MendeSMSusanne Mende
- Sigrid SchulteSSSigrid Schulte
- Ingo StrackISIngo Strack
- Heike HuntHHHeike Hunt
- Margarete OdenthalMOMargarete Odenthal
- Galyna PryymachuckGPGalyna Pryymachuck
- Maria QuasdorffMQMaria Quasdorff
- Münevver DemirMDMünevver Demir
- Dirk NierhoffDNDirk Nierhoff
- Hans-Peter DienesHDHans-Peter Dienes
- Tobias GoeserTGTobias Goeser
- Hans-Michael SteffenHSHans-Michael Steffen
- 18 December 2012
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 58 (5) , 1271-1281
Abstract
Background Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease leading to cirrhosis and cholangiocellular carcinoma. Inhibitors of the renin–angiotensin system or the sympathetic nervous system delay liver fibrogenesis in animal models. Aims We investigated the antifibrotic potential of telmisartan, an angiotensin II type 1 receptor antagonist, and the β-adrenoceptor blocker propranolol in the PSC-like Abcb4 knockout mouse model. Methods Sixty-five Abcb4−/− mice were treated with telmisartan for 3 or 5 months (T) and with telmisartan plus propranolol for 3, 5, or 8 months (TP), or for 2 or 5 months starting with a delay of 3 months (TP delayed). Liver hydroxyproline content, inflammation, fibrosis, and bile duct proliferation were assessed; fibrosis-related molecules were analyzed by real-time polymerase chain reaction and Western blotting. Results Compared to controls, telmisartan monotherapy had no significant influence on hydroxyproline; however, telmisartan plus propranolol reduced hydroxyproline (TP 3 months, p = 0.008), fibrosis score (TP 3 months and TP 8 months, p = 0.043 and p = 0.008, respectively; TP delayed 8 months, p < 0.0005), bile duct proliferation (TP 8 months and TP delayed 8 months, p = 0.006 and p < 0.0005, respectively), and procollagen α1(I), endothelin-1, TIMP-1 and MMP3 mRNA as well as α-SMA, CK-19, and TIMP-1 protein. Conclusions Telmisartan plus propranolol reduces liver fibrosis and bile duct proliferation in the PSC-like Abcb4−/− mouse model, even when started at late stages of fibrosis, and may thus represent a novel therapeutic option for cholestatic liver diseases such as PSC.Keywords
This publication has 50 references indexed in Scilit:
- Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosisAmerican Journal of Physiology-Renal Physiology, 2010
- Involvement of cholangiocyte proliferation in biliary fibrosisWorld Journal of Gastrointestinal Pathophysiology, 2010
- Matrix Metalloproteinase (MMP)-1 and MMP-3 Induce Macrophage MMP-9: Evidence for the Role of TNF-α and Cyclooxygenase-2The Journal of Immunology, 2009
- High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #Hepatology, 2009
- Cellular and molecular mechanisms of fibrosisThe Journal of Pathology, 2007
- Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genesJournal of Hepatology, 2005
- Hepatic fibrogenesis requires sympathetic neurotransmittersGut, 2004
- Dual Inhibition of β-Adrenergic and Angiotensin II Receptors by a Single AntagonistCirculation, 2003
- Reversal of left ventricular remodeling: Role of the endothelin pathwayJournal of Cardiac Failure, 2002
- Inhibition of rat liver fibrogenesis through noradrenergic antagonismHepatology, 2002